Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

BACKGROUND: Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to resistance to therapy. We have previously shown that the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Gao, Yanyun, Zens, Philipp, Su, Min, Gemperli, Camila Anna, Yang, Haitang, Deng, Haibin, Yang, Zhang, Xu, Duo, Hall, Sean R. R., Berezowska, Sabina, Dorn, Patrick, Peng, Ren-Wang, Schmid, Ralph Alexander, Wang, Wenxiang, Marti, Thomas Michael
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8056724/
https://ncbi.nlm.nih.gov/pubmed/33874986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01938-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados